Acuta Capital Partners LLC Takes $755,000 Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Acuta Capital Partners LLC purchased a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 740,000 shares of the biopharmaceutical company’s stock, valued at approximately $755,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. LPL Financial LLC increased its position in Sangamo Therapeutics by 113.5% in the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 16,498 shares during the last quarter. Northern Trust Corp raised its stake in Sangamo Therapeutics by 4.5% in the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 17,049 shares during the period. JPMorgan Chase & Co. lifted its holdings in Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 21,793 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter worth about $25,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.74 on Friday. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The firm’s fifty day moving average price is $0.81 and its 200-day moving average price is $1.37. The stock has a market cap of $166.56 million, a P/E ratio of -0.99 and a beta of 1.57.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Truist Financial cut their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Sangamo Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.17.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.